Eleusis is a pharmaceutical company that is developing serotonin 5-HT2A receptor agonists related to serotonergic psychedelics as novel anti-inflammatory drugs to treat inflammatory diseases.[1][2] It is interested in developing the drugs for treatment of conditions like asthma, cardiovascular disease, and Crohn's disease, but is initially focusing on ophthalmology.[2]
Its drug candidates include ELE-02 (2C-iBu) and its predecessor ELE-01, which are both phenethylamines.[1][3] It is developing ELE-02 as a topical eye drop to treat inflammatory